Partnering

 

ASINEX is interested in research, development and commercialization relationships with pharmaceutical and biotechnology companies.

 

 

ASINEX has mastered its Compound-to-Target™ platform that facilitates translation of innovative small molecule and macrocyclic chemistry into pre-clinical leads focusing on specific oncogenic pathways:

 

 

     ・ Apoptotic pathway

 

     ・ Cyclin-dependent kinase pathways

 

     ・ Wnt/β-catenin signaling pathway 

 

 

In addition to oncology, the platform provides valuable starting points for antibacterial R&D.

 

 

For more information, please contact us.

 

 

Top